Takeda’s Post

Participating in the #GRIDDStudy can significantly amplify the visibility of the struggles you experience as a skin disease patient. By becoming a part of this research, you contribute to a broader understanding of the issues involved, thereby attracting attention from medical professionals, policymakers, and the public. This heightened focus can pave the way for improved treatments and better support systems for individuals like yourself who are coping with skin conditions. Join the GRIDD Study now: https://lnkd.in/gkEyNjmk #Research #vitiligo #albinism #HS #EB #atopicdermatitis #hyperhidrosis #lupus #naevusflammeus #myositis #psoriasis #eczema #XP #ichthyosis #acne

#UCalgary researchers, led by Drs. Pietro Ravani, MD, PhD, and Ping Liu, PhD, are now able to predict kidney failure more accurately. A digital tool created by a team of University of Calgary scientists and international research partners is poised to become the new standard for predicting the risks of kidney failure and death in adults with moderate-to-severe kidney disease. The Kidney Foundation of Canada estimates that one in 10 Canadians have chronic kidney disease and the number of Canadians living with end-stage kidney disease is also increasing, up 35 per cent since 2009. Dr. Liu says the tool’s ability to more accurately predict the risk of kidney failure, and the likelihood of death from it, can improve treatment. Read the full story below. O'Brien Institute for Public Health | Libin Cardiovascular Institute | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | UCalgary Centre for Health Informatics | #ResearchMatters

Researchers at the University of Calgary, led by Drs. Pietro Ravani and Ping Liu, have developed KDpredict, a digital tool that advances how medical professionals predict kidney failure and mortality risks in chronic kidney disease (CKD) patients. Utilizing data from nearly 100,000 patients, KDpredict offers more accurate risk evaluations, aiding in the formulation of effective treatment strategies. This tool also considers comorbid conditions such as diabetes and heart disease, supporting personalized patient care. Read the full story at https://lnkd.in/gZ6RzTx9 Cumming School of Medicine UCalgary #UCalgary #UCalgaryMed #LibinInstitute #kidneydisease #chronickidneydisease #kidneyfailure #precisonmedicine

Such an amazing World Symposium on PH #WSPH we had! It was a great opportunity to network and meet friends and colleagues from around the world. Wonderful high-level discussions and some new treatment #opportunities for our patients. My favorite #HotTopic: why do #trials fail in PH associated with chronic lung diseases? 1. Appropriate patient population/phenotype: •Degree of parenchymal vs vascular derangement • Pre-capillary PH vs post-capillary vs combined pre/post capillary PH • Parenchymal diagnosis (ILD vs CPFE, specifically degree of emphysema) 2. Appropriate duration of trial 3. Choice of endpoint: PVR vs 6MWT vs a clinical combination endpoint 4. Choice of medication dose and route of administration We will be waiting for the upcoming publication of task forces recommendations!

One of the biggest research moments in TAPS was the TAPS registry - a collaboration between 17 fetal therapy centers worldwide. The resulting data was published in 3 papers - one specific to post-laser TAPS, one specific to spontaneous TAPS, and one overall paper. 370 cases of TAPS were analysed, and gave us some crucial insights into the management and treatment of this rare disease. More: https://bit.ly/304oAbB #internationaltapsday #tapsday #ITD2024 #tapsawareness #tapseducation

Evaluating disease-modifying therapies for Parkinson's disease (PD) requires exploring new methods to assess disease progression in the early stages of the disease. In the past few years, Modus Outcomes has contributed to several research collaborations on this stimulating question. Our latest research in this area was presented last week at International Congress of the International Parkinson and Movement Disorder Society in Copenhagen. In an analysis of data from the Parkinson’s Progression Markers Initiative (PPMI) de Novo PD cohort, we showed how a subset of 15 items from the part III (motor sign severity) of the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPRS) can be repurposed to create a promising measure of bradykinesia and rigidity, which are typical signs of early-stage PD. Read the abstract here: https://rb.gy/zv9o1 For more information on this research or on how Modus Outcomes can help with exploring novel endpoints for use in the development of therapies in atypical settings, please contact Tara Willoughby, Business Development Coordinator, Modus Outcomes (a division of THREAD). #PCOR #PatientVoice #ParkinsonsDisease #MovementDisorders #MDSCongress  

In collaboration with our Israeli partners, we're pleased to present the findings of the recent clinical study: "QMR Effects on Patients With Dry Eye Disease: A Randomized Controlled Trial." This study offers a fresh perspective on the use of #QMRtechnology in managing #dryeye disease, contributing valuable insights to the field. For a detailed look at the research and its outcomes, download the full study here 👉 https://lnkd.in/drc3Tgyr ___ #resono #qmr #ophthalmology #ded

Did you know there are 26 targeted therapies currently used for Immune-mediated Inflammatory Diseases (IMID’s)?   However, bridging the gap between IMID patients and effective targeted treatments remains a complex challenge. The trial-and-error process not only affects disease progression but also has a major psychological impact on patients.   Our recent article, Navigating Precision Medicine Challenges in IMIDs, explores the unique precision medicine challenges in IMID’s along with Diaceutics recommendations on how to address these.   Read the full article here: https://lnkd.in/dKuZ8Jeb #Precisionmedicine #IMID Inês Abrunhosa Amaral

Clinical Trials Unveiling the Human Side of Clinical Research A Complete Guide To Clinical Trial Market (e-pdf) Get a Free PDF Copy: https://lnkd.in/gv5vD4ME The growing prevalence of chronic diseases and the incidence of novel diseases is expected to boost the clinical trials market. According to the World Heart Report 2023, over half a billion people worldwide are affected by #Cardiovascular Diseases (CVDs), which caused over 20.5 million deaths in 2021. Furthermore, according to the Parkinson’s Foundation, approximately 1 million individuals in the U.S. currently suffer from Parkinson's Disease (PD), which is projected to increase to over 1.2 million by 2030. #market #marketreport #marketresearch #gobalmarket #researchindustry #gvr #clinicaltrial

As precision medicine inexorably shifts into chronic diseases the complexity of the diagnostic pathway increases, yet the benefit to reform those same pathways to channel patients to the optimal drug will prove the role precision medicine can play in value based care.